Latest News
|
More Articles...
- Portola Pharmaceuticals Announces Results Demonstrating Andexxa® was Associated with Lowest Rate of Mortality in Patients with Multiple Types of Factor Xa Inhibitor-Related Bleeds
- Biofourmis Partners with ImagineMIC to Pioneer Collaborative Remote Patient Monitoring Model
- The Cardiac Risk of Chloroquine in Unapproved Indications
- Bardy Diagnostics™ Announces Use of The Carnation Ambulatory Monitor Patch to Measure QT Segments in COVID-19 Patients Using Hydroxychloroquine
- FDA approves first generics of Eliquis
- HUYA Bioscience International® Announces the Successful Completion of Phase 1 Trial of HBI-3000
- Johnson & Johnson Launches Heartline™, the First-of-its-Kind, Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
- Large Real-World Data Confirm Safety and Effectiveness of LIXIANA®▼ (edoxaban) in Routine Clinical Practice for Elderly AF Patients with Comorbidities
- MediLynx Cardiac Monitoring, LLC introduces dedicated remote monitoring services based on its PocketECG® platform to support hospitals in managing COVID-19 patients in accordance with the latest FDA enforcement policy
- Milestone Pharmaceuticals Announces Topline Results from First-of-its-kind Phase 3 NODE-301 Trial of Etripamil for At-home Acute PSVT Treatment
|
|